Inner page banner-Company news


ASCO 2021| CD80 fusion protein, low concentration of global research projects, good time for layout
Not long ago, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Alpine Immune Sciences Inc (NASDQ: ALPN), a biotechnology company dedicated to the development of innovative therapies for tumors and autoimmune/inflammatory diseases, announced its CD80 fusion protein The data from the Phase 1 clinical trial of ALPN-202 for the treatment of patients with advanced solid tumors showed that its disease control reached 60%, and the trial did not find safe cases of cytokine risk.
Next page:Is the last one